Isenberg Jeffrey S, Kandeel Fouad
Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Department of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Cell Transplant. 2025 Jan-Dec;34:9636897241312801. doi: 10.1177/09636897241312801.
Islet transplantation (IT) is a successful natural cell therapy. But the benefits are known mostly to individuals with severe type 1 diabetes who undergo IT and the health care professionals that work to make the therapy available, reproducible, and safe. Data linking IT to overall survival in T1D might alter this situation and frame the therapy in a more positive light. Recent analysis of mortality in several cohorts suggests that IT has possible survival benefits when used alone or in conjunction with renal transplantation. Multi-center prospective studies with long-term follow-up of individuals that receive stand-alone IT versus individuals who qualify for but do not undergo the procedure would seem reasonable to undertake to confirm an IT survival benefit.
胰岛移植（IT）是一种成功的天然细胞疗法。但这种益处大多只为接受IT的重度1型糖尿病患者以及致力于使该疗法可用、可重复且安全的医护人员所知。将IT与1型糖尿病患者的总体生存率相关联的数据可能会改变这种情况，并以更积极的视角看待该疗法。最近对几个队列的死亡率分析表明，IT单独使用或与肾移植联合使用时可能具有生存益处。开展多中心前瞻性研究，对接受单独IT的个体与符合条件但未接受该手术的个体进行长期随访，似乎是合理的，以确认IT的生存益处。
